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Accidentally detected asymptomatic Wolff-Parkinson-White syndrome
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Introduction
Depression is reported to affect 6% of adolescents aged 
from 13 to 18 years [1] with high suicidality,  recurrence 
and chronicity [2, 3]. In adolescents with moderate to 
severe depression, pharmacological treatment in com-
bination with a psychological therapy is often indi-
cated [4]. As a result of lack of clinical trials in  children 
and adolescents, the off-label use of anti depressant 
drugs is widespread (about 49% of all antidepressant 
drugs prescribed) in this population [5]. Among these 
off-label prescriptions, the use of the  selective seroto-
nin reuptake inhibitors (SSRIs) is becoming preferred 
because of their safer cardiac  profiles compared with 
older medications such as tricyclic antidepressants.
Wolff-Parkinson-White (WPW) syndrome is a macro-
reentrant arrhythmia with an estimated prevalence of 
2–4 per 1000. A significant proportion of cases are 
found incidentally in asymptomatic patients present-
ing for routine checkups [6]. Conduction through an 
accessory pathway may cause preexcitation of the ven-
tricles leading to supraventricular  tachycardia, atrial 
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fibrillation, ventricular fibrillation and even cardiac 
 arrest [6].
In adolescents with preexisting cardiac disease, 
 depression and anxiety are commonly reported [7]. 
 SSRIs are generally recommended as first-line psycho-
tropic agents for depressed patients with heart failure 
[8] and improvement in depression was reported to be 
asso ciated with improved adherence to cardiovascular 
drug therapy in adults [9]. However, little is known 
about the use of SSRIs in youths with preexisting 
 cardiac disease, in particular, no cases have been pub-
lished on the use of SSRIs in adolescents with WPW 
syndrome. 
Case report
We report here the case of a 15-year-old girl who was 
admitted to our outpatient consultation for a severe 
depressive episode without psychotic symptoms (F32.2, 
ICD-10). She had a depressed mood from more than 
1 year together with disturbed sleep, loss of energy and 
of body weight, diminished ability to con centrate and 
a feeling of worthlessness. Recurrent thoughts of death 
were present. She scored six on the Clinical Global 
 Impression-Severity (CGI-S) scale, which classified her 
as “severely ill”. As past medical history, she was born 
prematurely and had been diagnosed with infantile 
 pyloric stenosis, which is rare in preterm infants 
 according to the literature [10, 11]. She was treated med-
ically at birth during a prolonged hospitalisation of 
3 weeks, but no additional information about her 
 initial treatment could be obtained. She later had sev-
eral standard electrocardiogram (ECG) recordings with 
normal results, according to the family. As she had no 
known history of substance use and cardiac disease, 
cardiac  arrest or related risk-factor, antidepressant 
treatment with sertraline was prescribed. The daily 
dose was increased gradually every six days from the 
 initial dose of 25 mg to 50 mg, and then to the mainte-
nance dose of 100 mg. The combination of psychologi-
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cal and pharmacological treatment resulted in a signif-
icant improvement from baseline in depressive 
symptoms. Her suicidal thoughts almost disappeared. 
After 3 months of treatment, she scored four on the 
CGI-S scale (“moderately ill”) and two on the Clinical 
Global Impression-Improvement (CGI-I) scale (“much 
improved”). 
Six months after starting sertraline, she underwent 
an endoscopic examination in order to investigate 
some recurrent gastric symptoms. The endoscopy 
 revealed no anomalies; however, asymptomatic WPW 
syndrome was found incidentally on ECG monitoring 
during the examination. She was  referred to a cardiol-
ogist for a further cardiovascular investigation. Holter 
monitoring revealed sinus rhythm with no QTc prolon-
gation, and a mean heart rate of 76 per minute but with 
a range from 42 to 167 leading to variable prolongation 
of the QRS complex, suggesting a left lateral accessory 
pathway. A few isolated supra ventricular and ventricu-
lar arrhythmias were observed. Such isolated paroxys-
mal arrhythmias did not allow measurement of the 
more specific anterograde characteristics of the acces-
sory pathway (in order to  assess its clinical gravity) 
with noninvasive evaluation (for example, the shortest 
preexcited R-R  interval on the ECG [SPERRI]). Echo-
cardiography was normal.  Electrophysiology studies 
were scheduled to investigate further the accessory 
pathway (with a subsequent radio frequency catheter 
ablation, if necessary). She received flecainide (100 mg/
day) as an antiar rhythmic treatment. 
Her residual depressive symptoms did not appear 
more important with the newly diagnosed cardiac dis-
ease. She ruminated a great deal on a theory of fatal-
ism, without any intentional suicidal thought or plan. 
She became sometimes more anxious, showing in-
tense emotional outbursts. The antidepressant treat-
ment with sertraline was estimated by the cardiologist 
as unlikely to be a cause for the development and evo-
lution of the asymptomatic WPW syndrome found in 
this patient. In addition, to our knowledge, WPW syn-
drome is considered to be a congenital condition and 
no cases of WPW syndrome induced by an SSRI are de-
scribed in the literature. Considering her residual 
 depressive symptoms and anxiety symptoms related 
to the newly diagnosed WPW syndrome, we proposed 
her to continue her psychological therapy and pharma-
cological treatment with sertraline (100 mg/day).
Discussion
In this case report, our patient was an adolescent girl 
presenting severe depressive symptoms before being 
diagnosed incidentally with WPW syndrome, a macro-
reentrant arrhythmia disorder with an estimated 
prevalence of 2–4 per 1000. A significant proportion of 
patients with asymptomatic WPW syndrome are found 
incidentally when presenting for routine checkups [6]. 
Population studies yielded variable but very low inci-
dences of sudden death [12]. Various recommendations 
on the management of asymptomatic young patients 
with WPW syndrome have been published [12].
The question arises on the choice of antidepressant 
treatment when psychological treatment alone is not 
adequate. In the USA, fluoxetine and escitalopram are 
approved by the Food and Drug Administration (FDA) 
for treatment of depression in paediatric patients 
(starting from 8 years and 12 years, respectively). In 
Switzerland, none of the SSRIs has been approved by 
Swiss Agency for Therapeutic Products (Swissmedic) 
for use in children and adolescents with depression. 
Fluvoxamine was approved by Swissmedic for use in 
children 8 years and older and sertraline in children 
6 years and older, but only for the treatment of obses-
sive-compulsive disorders. For this reason, but also 
 because of a  favourable cardiac safety profile, sertra-
line appears to be often used for the treatment of ado-
lescent depression in Switzerland (off-label). Of note, 
although the  SSRIs are considered to have generally 
safe cardiac  profiles, SSRI-related QTc prolongation 
and/or “torsades de pointes” have been reported [13, 
14]. However, a recent meta-analysis [14] concluded that 
QTc pro longation produced by SSRIs (other than citalo-
pram) seemed to be relatively small and was consid-
ered to be clinically insignificant for most patients. 
Sertraline, compared with other SSRI antidepressants, 
has been found to be safe for use in adult patients with 
preexisting cardiac disease [15, 16] and no torsades de 
pointes has been reported to be associated with single 
use of  sertraline [13]. In children and adolescents, the 
absence of cardiovascular adverse effects has been 
 reported for sertraline use at doses up to 200 mg [17]. 
It has been recommended that a baseline ECG is per-
formed when the patient has a suspicious medical 
 history or related risk factors for arrhythmia, or when 
the medication to be prescribed is documented to 
cause prolongation of the QTc interval at therapeutic 
doses [13]. Although careful risk-benefit analysis is 
 always necessary when antidepressant treatment is 
proposed, in particular in infants and adolescents 
[9, 15], an ECG check is not considered necessary be-
fore prescribing sertraline in the absence of a known 
history of cardiac disease or related risk factors [13]. 
In addition, persistent depression increases mortality 
in patients with cardiac disease and improvement in 
depression was reported to be associated with 
 improved adherence to cardiovascular drug therapy 
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[9]. The improvement in depressive symptoms and 
 absence of cardiac adverse effects in our adolescent pa-
tient after 5 months of antidepressant treatment with 
sertraline suggests the cardiac safety of sertraline at 
therapeutic doses in adolescents with preexisting but 
asymptomatic cardiac disease such as WPW syndrome. 
This is in accordance with early reports in adults with 
 preexisting heart disease [15, 16]. However, because of 
this single case, it is important to  emphasise necessary 
caution, in particular when combining psychotropic 
treatments, which could lead to severe cardiac events 
as demonstrated recently with sertraline plus mirta-
zapine [18], although single use of mirtazapine has 
been  reported to be efficient in treating depression in 
an  adolescent with preexisting cardiomyopathy and 
 arrhythmia [8].    
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